Bradmer Pharmaceuticals (TSE:GLX) Upgraded to “Strong-Buy” at Chardan Capital

Bradmer Pharmaceuticals (TSE:GLX) was upgraded by stock analysts at Chardan Capital to a “strong-buy” rating in a research report issued on Monday,Zacks.com reports.

Several other equities research analysts have also recently weighed in on GLX. ATB Cormark Capital Markets cut Bradmer Pharmaceuticals from a “strong-buy” rating to a “moderate buy” rating in a research note on Thursday, February 5th. Citigroup raised Bradmer Pharmaceuticals to a “hold” rating in a research note on Tuesday, February 24th. Four investment analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy”.

Bradmer Pharmaceuticals Stock Performance